Abstract
No public abstract is available from the verified source records.
Open public full textRights: ALLOWED · cc-by · Source: journal-auto-sync:external:CROSSREF_ISSN
Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureKarl Kunzelmann
The full-text link is unavailable.
Abstract
Rights: ALLOWED · cc-by · Source: journal-auto-sync:external:CROSSREF_ISSN
The full-text link is unavailable.
Authors
Institutions
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
europepmc
Confidence 96%
openalex
Confidence 95%
unpaywall
Confidence 95%
doaj
Confidence 92%
datacite
Confidence 0%
No local citing links have been materialized yet.
The full-text link is unavailable.
10.1016/j.lanepe.2021.100084
10.1016/j.lanepe.2021.100084
Niclosamide is a proton carrier and targets acidic endosomes with broad antiviral effects
10.1371/journal.ppat.1002976 · 2012
Drug repurposing: the anthelmintics niclosamide and nitazoxanide are potent TMEM16A antagonists that fully bronchodilate airways
10.3389/fphar.2019.00051 · 2019
TMEM16A in cystic fibrosis: activating or inhibiting?
10.3389/fphar.2019.00003 · 2019
Niclosamide repurposed for the treatment of inflammatory airway disease
2019
Repurposing salicylanilide anthelmintic drugs to combat drug resistant Staphylococcus aureus
10.1371/journal.pone.0124595 · 2015
COVID-19 vaccines: “Warp Speed” needs mind melds, not warped minds
10.1128/jvi.01083-20 · 2020
Maintaining safety with SARS-CoV-2 vaccines
10.1056/nejmra2035343 · 2021
Covid-19 and immunity in aging populations - a new research agenda
10.1056/nejmp2006761 · 2020
The potential danger of suboptimal antibody responses in COVID-19
10.1038/s41577-020-0321-6 · 2020
No additional external references are available.